Home world Registry Data Reveals Safety of COVID-19 Vaccines

Registry Data Reveals Safety of COVID-19 Vaccines

COVID Vaccine Options

COVID Vaccine Options

Registry data reveals safety of

The results from COVAX show that the majority of people with inflammatory RMDs tolerate their COVID vaccine well – with no difference in safety profile to that seen in the general population or people with non-inflammatory RMDs. The most common side effects were short-lived reactions to the injection. One of the reasons for asking additional safety questions in people with inflammatory RMDs is the concern that the vaccine could cause a disease flare. In this study, only 4.4% of people experienced a flare after having their COVID vaccine, and only 0.6% were classed as severe. The majority of people (over 98%) were able to continue on their normal medication with no changes. The study also found there was a low rate of COVID-19 infections in people with RMDs once they were fully vaccinated.

These are valuable findings which will support discussions about the safety and benefit/risk ratio of COVID vaccination for people with RMDs. The information will also be useful for the development of new and updated recommendations.

Reference: “Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry” by Pedro M Machado, Saskia Lawson-Tovey, Anja Strangfeld, Elsa F Mateu, Kimme L Hyrich, Laure Gossec, Loreto Carmona, Ana Rodrigues, Bernd Raffeiner, Catia Duarte, Eric Hachulla, Eric Veillard, Eva Strakova, Gerd R Burmester, Gözde Kübra Yardimci, Jose A Gomez-Puerta, Julija Zepa, Lianne Kearsley-Fleet, Ludovic Trefond, Maria Cunha, Marta Mosca, Martina Cornalba, Martin Soubrier, Nicolas Roux, Olivier Brocq, Patrick Durez, Richard Conway, Tiphaine Goulenok, Johannes WJ Bijlsma, Iain B McInnes and Xavier Mariette, 31 December 2021, Annals of the Rheumatic Diseases.
DOI: 10.1136/annrheumdis-2021-221490

Previous articleiQOO 9 series confirmed to launch soon in India
Next articleSamsung guidance shows Q4 was another record-breaking quarter


Please enter your comment!
Please enter your name here